Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer.

Yusuke KajimotoTakashi ShibutaniShoji NagaoSatoshi YamaguchiShiro SuzukiMasahiko MoriHirofumi TsubouchiKohshiro NakaoAnri AzumaTakahiro KoyanagiIzumi KoharaShuko TamakiMidori YabukiLida TengKazunori HondaAtaru Igarashi

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)

The COST tool has good internal consistency and reliable reproducibility in patients with gynecologic cancer in Japan. The COST tool quantifies financial toxicity in the insurance system, where patients have limited out-of-pocket direct medical costs. The results support the use of the COST tool in patients with gynecologic cancer.

Keyphrases

papillary thyroid
squamous cell
childhood cancer
oxidative stress
newly diagnosed
end stage renal disease
ejection fraction
lymph node metastasis
affordable care act